Novartis AG
Pharmaceutical & Health Products · Lobbying Client
B
Influence Score
62/100
High Influence
$12.2M
Total Lobby Spend
5
Policy Issues
5
Lobbyists
2
Revolving Door
Novartis AG reported $12.2 million in federal lobbying expenditures as disclosed in Senate LDA filings. The organization's lobbying activity spans 5 policy areas, with primary focus on Health Issues, Pharmacy, Medical/Disease Research. This data is drawn from quarterly disclosure reports filed with the Secretary of the Senate under the Lobbying Disclosure Act of 1995.
Annual Lobbying Spend
Policy Issues
Government Entities Contacted
Food & Drug Administration
Dept of Justice
Office of Management & Budget
National Science Foundation
Dept of Commerce
Dept of Defense
Federal Energy Regulatory Commission
Recent Filings
| Period | Registrant | Issues | Lobbyists | Amount |
|---|---|---|---|---|
| 2020 Jan-Mar | Covington & Burling LLP | TRDMEDPHA | 3 | $561K |
| 2020 Apr-Jun | K&L Gates LLP | GOVMEDPHA+2 | 1 | $516K |
| 2020 Jul-Sep | Akin Gump LLP | GOVMEDHCR+2 | 3 | $788K |
| 2020 Oct-Dec | BGR Group LLP | TRDPHAHCR+2 | 1 | $578K |
| 2021 Jan-Mar | Akin Gump LLP | PHAGOVMED+2 | 1 | $745K |
| 2021 Apr-Jun | Covington & Burling LLP | HCRMED | 1 | $742K |
| 2021 Jul-Sep | Squire Patton Boggs LLP | TRDHCRMED | 4 | $636K |
| 2021 Oct-Dec | Squire Patton Boggs LLP | TRDHCR | 1 | $557K |